Last reviewed · How we verify
Cali Pharmaceuticals LLC — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
3 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Naropin, 0.5% Injectable Solution | Naropin, 0.5% Injectable Solution | phase 3 | Local anesthetic | Voltage-gated sodium channels | Pain management | |
| Local anesthetic injection of CPL-01 | Local anesthetic injection of CPL-01 | phase 3 | Local anesthetic | Pain Management / Anesthesia | ||
| CPL-01 | CPL-01 | phase 3 | SGLT2 inhibitor | SGLT2 | Diabetes |
Therapeutic area mix
- Diabetes · 1
- Oncology · 1
- Pain Management / Anesthesia · 1
- Pain management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Medical University of Vienna · 2 shared drug classes
- University of California, San Diego · 2 shared drug classes
- Beijing Tiantan Hospital · 2 shared drug classes
- Centre Hospitalier Universitaire de Saint Etienne · 2 shared drug classes
- Pfizer · 2 shared drug classes
- Second Affiliated Hospital, School of Medicine, Zhejiang University · 2 shared drug classes
- Ain Shams University · 2 shared drug classes
- University of Colorado, Denver · 2 shared drug classes
Subscribe to ongoing alerts
Every new pipeline event for Cali Pharmaceuticals LLC:
- Cali Pharmaceuticals LLC pipeline updates — RSS
- Cali Pharmaceuticals LLC pipeline updates — Atom
- Cali Pharmaceuticals LLC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Cali Pharmaceuticals LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cali-pharmaceuticals-llc. Accessed 2026-06-10.